USD10
IMTX Shares
About ImmaticsImmatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
USD10
IMTX Shares
About ImmaticsImmatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Stats
TRADING WINDOW
Closed
OPENS AT
Apr 1 at 1:30 PM GMT+0
MARKET CAP
$1.32B
OPEN PRICE
Not enough data
LOW (1Y)
$3.30
HIGH (1Y)
$12.41
LOW (24H)
$9.52
HIGH (24H)
$9.94
VOLUME (24H)
$93.30K
13.29%
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $9.52 | |
1 Week | $9.85 | |
1 Month | $9.81 | |
1 Year | $4.17 |
Past performance is not a reliable indicator of future results.
Discover more
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.
